Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: HEALTH

Lui Franciosi To Monitor the Safety and Efficacy of Nebulized Heparin for the Treatment of COVID-19


VANCOUVER, British Columbia, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Lui Franciosi will be monitoring the safety and efficacy of nebulized heparin for the treatment of SARS-CoV-2, i.e., COVID-19. There is suggestion that unfractionated heparin has the potential to reduce mortality in COVID-19 patients. The virus induces acute respiratory distress syndrome (ARDS), which displays itself as diffuse alveolar damage with extensive pulmonary coagulation, fibrin deposition and formation of hyaline membranes in the air sacs. Heparin's anti-coagulant actions limit fibrin deposition and microvascular thrombosis within the lung. Lui Franciosi states, "I will be reviewing the scientific literature and online media reports from various countries to determine heparin's effects in large scale clinical trials, especially in seniors. The results of my review can be useful for administrators of long term care, assisted living and independent living to help them prepare for future COVID-related pandemics."   This review will be in the form of a white paper, which also be made available to seniors, families and the general public for their consideration.

For more information about Lui Franciosi and his company Franciosi Consulting Ltd., please visit https://franciosiconsulting.com/ or his YouTube Channel https://www.youtube.com/channel/UC7PSoeH8yN-HuLg5xFi5Qxw/. Dr. Franciosi advises on the operational and research needs of the pharmaceutical and senior care industries. He also discusses topics online such as running your own business, chronic pain, the importance of senior care, Lyme Disease, as well as COVID-19 & the Pfizer/BioNTech and Moderna vaccines.

About Lui Franciosi

Lui Franciosi is a pharmacologist and consultant with over 20 years of executive experience collected in the pharmaceutical and senior care industries. He holds a Masters degree and a Doctorate from the University of British Columbia in Vancouver, Canada. He also studied business at the University of Warwick in the U.K. Lui Franciosi founded Franciosi Consulting Ltd. in 2015 and is the President and CEO.   He is currently also an Adjunct Professor at The University of British Columbia and Simon Fraser University in areas of pharmacology and gerontology, respectively.

Contact
[email protected]
+1.778.998.6260



These press releases may also interest you

at 08:45
MastercardBy Vicki HymanPhilanthropist Melinda French Gates, right, spoke with Rosario Dawson, an actor and activist for gender equality, left, and Fatoumata Bâ, center, the founder and executive chair of Janngo Capital, about how to close the...

at 08:45
The Quest Diagnostics Foundation today announced an expanded collaboration with Green Bronx Machine (GBM), a transformational educational nonprofit...

at 08:35
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor...

at 08:25
NOVA LEAP HEALTH CORP. ("Nova Leap" or "the Company"), a growing home health care organization, is pleased to announce that it has executed a definitive agreement (the "Agreement"), dated April 25, 2024, to acquire a home care services company ("the...

at 08:20
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya's Scientific Advisory...

at 08:09
Adyton Resources Corporation announces that it has filed its financial statements for the three and twelve months ended December 31, 2023 and accompanying Management Discussion and Analysis on its SEDAR profile at www.sedar.com. ...



News published on and distributed by: